To synthesize current evidence on the epidemiology, pathophysiology, clinical presentation, diagnostic criteria, and management of MIS-C as a postinfectious condition related to COVID-19.
Key Findings:
MIS-C is a postinfectious hyperinflammatory disorder occurring 2 to 6 weeks after SARS-CoV-2 infection.
Clinical features include persistent fever, shock, and multiorgan involvement.
Management includes supportive care, hemodynamic stabilization, and immunomodulation with IVIG, corticosteroids, and biologics.
Thromboprophylaxis is often necessary due to increased thromboembolic risk.
Mortality rates for MIS-C range from 1% to 2%, with most patients recovering fully with appropriate treatment.
It is crucial to distinguish MIS-C from other similar inflammatory conditions.
Interpretation:
MIS-C presents significant clinical challenges due to its similarity to other inflammatory conditions and the lack of consensus on treatment protocols, which complicates diagnosis and management.
Limitations:
Diagnostic ambiguity and heterogeneous management guidelines.
Limited understanding of the exact pathogenesis of MIS-C.
Lack of consensus on treatment protocols.
Conclusion:
Timely immunomodulatory therapy is crucial for recovery, and long-term follow-up is necessary to monitor for complications.
